Document Detail

Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake?
MedLine Citation:
PMID:  23318283     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: : Pregabalin has an abuse potential and is occasionally used as a recreational drug. To draw the right conclusions regarding new intake of pregabalin in situations of repeated urinary drug testing, the knowledge of its disappearance rate in urine is essential.
METHODS: : One healthy male volunteer took a single oral dose of pregabalin at 2 occasions, first 75 mg and thereafter 150 mg. All urine was collected in 8-hour portions for 5 days and analyzed for pregabalin. A systematic search for literature describing concentrations of pregabalin in urine was performed, and the results from these studies were interpreted on the basis of the findings from the healthy volunteer.
RESULTS: : In the healthy volunteer, specimens remained positive for 56 hours after intake of 75 mg and for 64 hours after intake of 150 mg. Urinary elimination half-lives based upon creatinine-normalized concentrations were 5.7-5.9 hours. The systematic literature search revealed only 1 article describing urinary concentrations of pregabalin. In that study, including 4799 urinary samples, the median concentration was not higher than the initial concentration found in the healthy volunteer. By applying a urinary elimination half-life of 6 hours on that material, at least 50% would be expected to have negative urine specimens within 3 days and a total of 5 days would be needed to achieve negative urine specimens in the subject with the maximum urinary concentration measured.
CONCLUSION: : In subjects with normal renal function, it seems highly unlikely that a urine specimen should remain positive for pregabalin for more than 5-6 days after intake.
Olav Spigset; Andreas A Westin
Related Documents :
17881143 - Total body irradiation, toward optimal individual delivery: dose evaluation with metal ...
10464923 - Absorbed doses to patients from 191pt-, 193mpt- and 195mpt-cisplatin.
1381463 - Effects of antioxidants on induction of micronuclei in rat peripheral blood reticulocyt...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  35     ISSN:  1536-3694     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  137-40     Citation Subset:  IM    
*Department of Clinical Pharmacology, St. Olav University Hospital †Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Discrimination of prohibited oral use from authorized inhaled treatment of budesonide in sports.
Next Document:  Comparison of clinical and laboratory characteristics between children and adults with dengue.